<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03329638</url>
  </required_header>
  <id_info>
    <org_study_id>012701LT</org_study_id>
    <nct_id>NCT03329638</nct_id>
  </id_info>
  <brief_title>A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE)</brief_title>
  <official_title>A Phase II, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution Compared With Placebo in Subjects With Mild or Moderate Myopia (APPLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety and efficacy of three concentrations of DE-127 ophthalmic solution&#xD;
      when compared to Placebo in subjects diagnosed with mild or moderate myopia.&#xD;
&#xD;
      To investigate the dose response of DE-127.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2017</start_date>
  <completion_date type="Actual">April 9, 2020</completion_date>
  <primary_completion_date type="Actual">September 12, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spherical equivalent</measure>
    <time_frame>Month 12</time_frame>
    <description>Change from Baseline in spherical equivalent determined by cycloplegic autorefraction at Month 12 in the study eye.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>DE-127 Ophthalmic Solution low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DE-127 Ophthalmic Solution medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DE-127 Ophthalmic Solution high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Ophthalmic Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-127 Ophthalmic Solution low dose</intervention_name>
    <description>Low dose of DE-127 Ophthalmic Solution dosed once daily for 12 months</description>
    <arm_group_label>DE-127 Ophthalmic Solution low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-127 Ophthalmic Solution medium dose</intervention_name>
    <description>Medium dose of DE-127 Ophthalmic Solution dosed once daily for 12 months</description>
    <arm_group_label>DE-127 Ophthalmic Solution medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-127 Ophthalmic Solution high dose</intervention_name>
    <description>High dose of DE-127 Ophthalmic Solution dosed once daily for 12 months</description>
    <arm_group_label>DE-127 Ophthalmic Solution high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Ophthalmic Solution</intervention_name>
    <description>Placebo Ophthalmic Solution dosed once daily for 12 months</description>
    <arm_group_label>Placebo Ophthalmic Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Refractive error of spherical equivalent -1.0 diopter to -6.0 diopter in both eyes&#xD;
&#xD;
          -  Anisometropia of spherical equivalent less than or equal to 1.50 diopter in both eyes&#xD;
&#xD;
          -  Distance vision correctable to logMAR 0.2 or better in both eyes&#xD;
&#xD;
          -  Normal intraocular pressure of not greater than 21 mmHg in both eyes&#xD;
&#xD;
          -  No allergy to atropine, cyclopentolate, proparacaine and benzalkonium chloride&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Amblyopia or manifest strabismus including intermittent tropia&#xD;
&#xD;
          -  Ocular disorders that potentially affect myopia or refractive power&#xD;
&#xD;
          -  Previous or current use of contact lenses, bifocal lenses, progressive addition&#xD;
             lenses, or other forms of treatment (including atropine and pirenzepine) for myopia&#xD;
&#xD;
          -  Systemic disorders that potentially affect myopia or refractive power&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Singapore National Eye Centre</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>August 25, 2020</last_update_submitted>
  <last_update_submitted_qc>August 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

